title: Management of gastric cancer.
abstract: OBJECTIVE
  Gastric cancer is an uncommon cancer in the United States but is a very common cancer globally and is endemic in East Asia. It is a virulent cancer that presents with metastatic disease in about one half of United States patients.
  
  
  RESULTS
  In this review article, we discuss palliative chemotherapy options as well as validated preoperative, perioperative and postoperative strategies for locally advanced disease, which include chemotherapy and/or chemoradiation.
  
  
  CONCLUSIONS
  In the metastatic setting, there has been incremental improvement in cytotoxic chemotherapy combinations in the past 2 decades. Two targeted agents - trastuzumab and ramucirumab - are now approved. In the locally advanced setting, perioperative chemotherapy or postoperative chemotherapy or chemoradiation improves outcomes relative to surgery alone.
authors.affiliation: Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
authors.forename: Geoffrey Y
authors.initials: GY
authors.lastname: Ku
authors.forename: David H
authors.initials: DH
authors.lastname: Ilson
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002985:Clinical Protocols; D005743:Gastrectomy; D006801:Humans; D020360:Neoadjuvant Therapy / Q000379:methods; D009367:Neoplasm Staging; D010166:Palliative Care / Q000379:methods*; D018714:Radiotherapy, Adjuvant; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D014481:United States
chemical_list: D000970:Antineoplastic Agents